컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

International Stroke Conference (ISC) 2026

04 February - 06 February, 2026, United States

Traditional Chinese medicine combo shows therapeutic potential in disabling stroke

2026-03-04

The Chinese medicinal combination chuanzhi tongluo, when added to standard medical therapy, helps improve the likelihood of achieving a good functional outcome without increasing the risk of intracranial haemorrhage in patients with disabling stroke without visible large or medium vessel occlusion, as shown in the CONCERN trial.
Novel loberamisal neuroprotectant boosts functional recovery from stroke

2026-03-04

Among patients with acute ischaemic stroke, administration of loberamisal, a novel neuroprotective agent, within 48 hours of symptom onset improves functional outcomes, according to the LAIS* trial presented at ISC 2026.
Tenecteplase bests alteplase for distal occlusions

2026-03-04

In the secondary analysis of the TASTE trial, tenecteplase is associated with better clinical outcomes than alteplase in individuals with distal vessel occlusions (DVOs).
Intra-arterial alteplase after successful EVT yields excellent functional outcome in adults

2026-03-04

The use of intra-arterial (IA) alteplase following a successful endovascular thrombectomy (EVT) improves 90-day functional outcome in patients with large-vessel occlusion (LVO) acute ischaemic stroke compared with EVT-alone, according to the CHOICE 2* trial presented at ISC 2026.
Adjunct tirofiban plus IVT safely improves functional outcomes in AIS

2026-03-04

Treatment with the short-acting glycoprotein IIb/IIIa inhibitor tirofiban after intravenous thrombolysis (IVT) results in significant improvements in 90-day functional outcomes among patients with acute ischaemic stroke, with no increase in haemorrhage or mortality, a study has shown.
GLP-1 RAs may lower long-term mortality risk in AIS patients

2026-03-04

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appears to contribute to a long-term reduced risk of death in patients with acute ischaemic stroke (AIS), suggests a study. However, less than 1 percent of these individuals have been prescribed GLP-1 RAs upon discharge.
CHOICE-2 strengthens case for administering intra-arterial lytic after thrombectomy

2026-03-04

For patients with acute ischaemic stroke caused by a large-vessel occlusion, infusing alteplase into the artery after successful endovascular thrombectomy is beneficial, conferring functional gains and reducing persistent hypoperfusion, as shown in the phase III open-label CHOICE-2 trial.
EVT improves functional outcomes in select stroke patients

2026-03-04

Results from the Oriental MeVo trial show that endovascular thrombectomy (EVT) within 24 hours of symptom onset significantly improves functional outcomes in individuals with medium vessel occlusion (MeVO) stroke and moderate-to-severe deficits.
Oral FXIa inhibitor reduces stroke recurrence without increasing major bleeding events

2026-03-04

The oral factor XIa (FXIa) inhibitor asundexian scores high for secondary prevention in patients with non-cardioembolic stroke or high-risk transient ischaemic attack (TIA) who are receiving standard antiplatelet therapy, having met its primary efficacy and safety endpoints in the phase III OCEANIC-STROKE trial.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2026 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브